Cancer Patient Testimonials    

















Poly MVA Survivors
Testimonials Written by Cancer Patients 
.
     
HOME TESTIMONIALS POLY-MVA RESEARCH WHAT YOU MUST KNOW

   
  Scientific Research
 
       
KGK Synergize
Independent Lab Tests
on 8 Cancer Cell Lines
Oncology Study
Board Certified Oncologist
1,000 Patient/Stage IV Study
Published Articles
Poly-MVA/Palladium-α-Lipoic Acid
articles on Pubmed.com
Poly MVA Inventor
See List of Patent filings
for Dr. Merrill Garnett
       
 
 
 
Poly MVA Research Scientists and Oncology Studies
 
Poly MVA Laboratory

Lung Cancer Study

Low Dose Chemo Report

Stage 4 Oncology Studies

Senior Scientist & Director of Clinical Research at Garnett Mckeen Labs

Frank Antonowich PhD
READ REPORT
 
Alternative and Complementary Therapies 12(2):77-80 · April 2006

Published Scientific Study

READ REPORT
 
The Role of Lipoic Acid Mineral
Complex in Integrative Oncology

Oncology Study Overview
READ REPORT
 
Board Certified Oncologist
Integrative Oncology

James W. Forysythe, M.D. H.M.D.
READ REPORT
 
 

 
 
Online Poly MVA Articles
 
Cancer Tutor

hill
Naturopathic Medicine

Cancer-Stroke-Anti-Aging

Tumor Specific Killing

Revealing cutting edge and
relevant natural treatments

READ REPORT
 
Published on November 20th, 2017
by Dr. Jennifer Nardella


READ REPORT
 
Published on August 1, 2013
by Dr. Cristopher Calapai D.O

READ REPORT
 
Treating Cancer Without Injury
Tumor Cell Specific Killing

READ REPORT
 
 
 
 
 
 
   
   
............
In 2007, KGK Science, Inc., an independent laboratory in Canada, examined the effects of POLY-MVA on 8 cancer cell lines.

These lines included:
1) Skin melanoma, human (SKMel-5)
2) Liver, hepatocellular carcinoma, human (Hep G2)
3) Lung, malignant melanoma, human (Malme-3M)
4) Mammary gland, ductal carcinoma, human (MDA-MB 435)
5) Prostate, left supraclavicular lymph node carcinoma, human (LNCaP)
6) Colon, colorectal adenocarcinoma, human (HT-29)
7) Human brain, glioblastoma; astrocytoma (U87)
8) Glioblastoma (HT-80)
 
POLY-MVA was administered at 3 different dosages and the number of cells was examined after 24, 48 and 72 hours following initial application. POLY-MVA was effective, to varying degrees, on the entire group of cell lines tested
(melanoma, liver, lung, breast, prostate, colon, astrocytoma and glioblastoma).
.
The varying effectiveness appears to be a consequence of the particular cell lines used and their associated degree of anaplasia.
 
The graph below demonstrates the benefit of POLY-MVA after 48 hours of initial exposure:
The Y-axis represents the number of cells per mL.
 
 
 
 
Poly MVA causes significant cell death after 48 Hours of exposure 
per mL.  SHAPE  \* MERGEFORMAT CPM
The table below illustrates the statistically significant level of cell death
(p must be equal to or less than 0.05) induced by POLY-MVA after 48 hours of initial exposure: 

 

Cancer Cell Type

 

 

Cell Line

Statistical Significance

 

Dosages (ug/ml)

Melanoma

SKMel-5

p<0.01

100, 1000

Liver

Hep G2

p<0.01

1000

Lung

Malme-3M

p<0.0004

100, 1000

Breast

MDA-MB 435

p<0.001

1000

Prostate

LNCaP

p<0.0005

1000

Colon

HT-29

p<0.03

10, 100, 1000

Astrocytoma

U-87

p<0.05; p<0.01

10, 100; 1000

Glioblastoma

HT-80

p<0.0001

10, 100, 1000

 
 
 
Garnett McKeen In vitro Cancer Assays:
Garnett McKeen Laboratory Inc. (GML) chose to mimic the National Cancer Institute’s (NCI) cell screening protocol.
 

The following cell lines were selected from the NCI repository:

MCF-7 (breast adenocarcinoma), and A549 (lung non-small cell adenocarcinoma).

 

The data below represents the completion of the Breast Cancer (MCF-7), Ovarian Cancer (OVCAR-5) and Lung Carcinoma (A549) assay.

 

We have also completed assays using stage IV glioblastoma multiforme (H-80) and astrocytoma (H-4) brain tumor lines.

 

As noted below, all of the studies demonstrated significant cell death.

 
 

.
CANCER CELL DEATH RATE IN 5 CELL LINES 
After 48 hours of exposure
 
 

Breast Cancer

(Adenocarcinoma)

91.1%

Breast Cancer Cell Death after 48 Hours

Ovarian Cancer

(Adenocarcinoma)

92.07%

Ovarian Cancer Cell Death after 48 Hours

 
 
 

Lung Cancer

(Non-Small Cell Carcinoma)

83.8% Percentage

Lung Cancer Cell Death after 48 Hours

 

 
 
Brain Tumor
(Glioblastoma)
96.3% Percentage
Brain Cancer Cell Death after 48 Hours
Brain Tumor
(Astrocytoma)
82.5% Percentage
Brain Cancer Cell Death after 48 Hours
   
 

 


 

.
For Doctors and Patients
.


Oncologist touts the benefits of Poly-MVA(LAMC)

.

James Forsythe, MD, HMD

Century Wellness Clinic in Reno, NV

.

"The long-term positive impact I have seen in our clinic is quite astounding. Since 2004, we've performed 3 outcome studies in over 1700 patients with Poly-MVA(LAMC).

.

Poly-MVA provides a significant difference as a stand-alone or Integrative Protocol and also continues to show outstanding impact for each patient's success & overall health."

Stage IV Study -  1,000 Patients
.


 
.
 
©2017 All Rights Reserved
 
The Poly MVA Survivors website is designed for educational purposes only, and is not engaged in rendering specific medical advice or professional services. The information provided through this website should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care.